Danielle Roman, PharmD, BCOP, explains why a collaborative, team-based approach is essential to solving resource challenges ...

Nirogacestat therapy shows sustained benefits, including tumor shrinkage and durable responses, in long-term treatment of ...

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

The American Journal of Managed Care® ( AJMC®) hosted its annual event, Patient Centered-Oncology Care (PCOC), on September ...

The data presented covered everything from its mainstay acalabrutinib, sold as Calquence, to the eye-catching AZD0120, an ...

Here are the top 5 soft tissue sarcoma articles of 2025: ...

Medicare HIV cases are projected to double by 2035, with cumulative costs reaching $195.6 billion and creating critical challenges for federal funding.

The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...

Our top 5 highlights from the 2025 San Antonio Breast Cancer Symposium (SABCS) include articles and interviews introducing ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Molecular ESR1 changes may signal symptomatic progression before imaging in metastatic breast cancer, supporting camizestrant for improved quality of life.

The US saw several new and expanded FDA indications this year. The top 5 most-read FDA approvals on AJMC.com included 4 novel ...